TNF receptor-associated factor 6 (TRAF6) mRNA (TRAF6 mRNA)

TNF receptor-associated factor 6 (TRAF6) mRNA is the transcript encoding the TRAF6 protein, a pivotal E3 ubiquitin ligase and adapter molecule in the Toll-like receptor (TLR), Interleukin-1 receptor (IL-1R), and Tumor Necrosis Factor (TNF) receptor signaling pathways [UniProt Q9Y4K3, NCBI Gene 7189]. Upon translation, the TRAF6 protein facilitates the activation of downstream effectors such as NF-kappaB and Mitogen-Activated Protein Kinases (MAPKs), which are essential for innate immunity, inflammatory responses, and bone homeostasis [UniProt Q9Y4K3, Starczynowski et al., Nature Medicine 2010]. Dysregulation or overexpression of TRAF6 mRNA is a hallmark of several hematopoietic disorders, most notably Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML), where it promotes cell survival and contributes to the characteristic cytopenias [Starczynowski et al., Nature Medicine 2010, Fang et al., Blood 2017]. Because the TRAF6 protein has been historically difficult to target with small-molecule inhibitors, therapeutic efforts have shifted toward targeting its mRNA using RNA interference (RNAi) or antisense oligonucleotides (ASOs) [Starczynowski et al., Nature Medicine 2010, Fang et al., Blood 2017]. These approaches aim to selectively degrade the TRAF6 transcript, thereby reducing protein levels and dampening the aberrant signaling driving disease progression [Fang et al., Blood 2017]. Additionally, TRAF6 mRNA levels are regulated by microRNAs such as miR-146a, and the loss of this regulation is a key driver in the pathogenesis of 5q- syndrome [Starczynowski et al., Nature Medicine 2010].

Other names

TRAF6 transcriptRNF74 mRNAMGC:3310 mRNATNF receptor-associated factor 6 transcript

RNA interference (RNAi) mediated mRNA degradation or antisense-mediated RNase H cleavage, leading to reduced translation of the TRAF6 protein [Fang et al., Blood 2017, Starczynowski et al., Nature Medicine 2010].